AR109093A1 - Solución oral que comprende clorhidrato de atomoxetina y sus métodos - Google Patents
Solución oral que comprende clorhidrato de atomoxetina y sus métodosInfo
- Publication number
- AR109093A1 AR109093A1 ARP170102007A ARP170102007A AR109093A1 AR 109093 A1 AR109093 A1 AR 109093A1 AR P170102007 A ARP170102007 A AR P170102007A AR P170102007 A ARP170102007 A AR P170102007A AR 109093 A1 AR109093 A1 AR 109093A1
- Authority
- AR
- Argentina
- Prior art keywords
- atomoxetine
- pharmaceutical composition
- oral
- flavoring
- aqueous solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composición farmacéutica oral en la forma de una solución acuosa de atomoxetina como un ingrediente activo. La solución acuosa de atomoxetina comprende un portador líquido de sabor enmascarado que comprende menta, saborizante de naranja y un agente viscosante. Los saborizantes combinados enmascaran el olor y/o el sabor amargo del clorhidrato de atomoxetina que la convierte en una composición farmacéutica de sabor agradable. El agente viscosante mejora la consistencia de la composición farmacéutica oral y proporciona una textura suave que la hace fácil de tragar. Más específicamente, la composición farmacéutica oral comprende cantidades efectivas de: (a) atomoxetina o sus sales farmacéuticamente aceptables; y (b) un portador líquido de sabor enmascarado. Además, un método para preparar la solución acuosa de atomoxetina. También métodos de uso de la composición farmacéutica oral para el tratamiento de un sujeto que tiene un trastorno tratable por administración de atomoxetina. En una forma de realización, el trastorno es trastorno de hiperactividad con déficit de atención (ADHD). Reivindicación 1: Una composición farmacéutica caracterizada porque comprende (i) 0 5 mg/ml a 25 mg/ml de atomoxetina y (ii) un portador que comprende: 0,01 mg/ml a 5 mg/ml de saborizante de menta, 0,01 mg/ml a 10 mg/ml de saborizante de naranja y 0,5 mg/ml a 600 mg/ml de uno o varios endulzantes, en donde la composición farmacéutica es una solución oral homogénea y en donde el pH de la composición va de 4 a 6,5. Reivindicación 15: Una composición farmacéutica caracterizada porque consiste esencialmente en: 1 - 10 mg/ml de clorhidrato de atomoxetina, 50 - 100 mg/ml de glicerol, 50 - 100 mg/ml de endulzantes, 200 - 300 mg/ml de SBE-b-CD, 0,2 - 5 mg/ml de saborizante de menta, 0,1 - 10 mg/ml de saborizante de naranja y 0,5 - 10 mg/ml de pululano y en donde el pH de la composición va de 4 a 6,5.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/379,142 US9855228B1 (en) | 2016-12-14 | 2016-12-14 | Oral solution comprising atomoxetine hydrochloride and methods thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AR109093A1 true AR109093A1 (es) | 2018-10-24 |
Family
ID=60805329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170102007A AR109093A1 (es) | 2016-12-14 | 2017-07-18 | Solución oral que comprende clorhidrato de atomoxetina y sus métodos |
Country Status (5)
Country | Link |
---|---|
US (2) | US9855228B1 (es) |
CN (1) | CN110035741B (es) |
AR (1) | AR109093A1 (es) |
TW (1) | TWI646958B (es) |
WO (1) | WO2018111345A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111437247A (zh) * | 2019-01-17 | 2020-07-24 | 北京万全德众医药生物技术有限公司 | 一种托莫西汀口服液的制备方法 |
CN111956607A (zh) * | 2020-09-25 | 2020-11-20 | 健民药业集团股份有限公司 | 盐酸托莫西汀口服溶液及其制备方法 |
CN113069496B (zh) * | 2021-03-18 | 2022-09-06 | 济川药业集团有限公司 | 用于治疗小儿感冒的中药颗粒组合物及制备方法 |
CN115778895B (zh) * | 2022-11-30 | 2024-04-26 | 江苏广承药业有限公司 | 一种盐酸托莫西汀口服溶液 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5891801A (en) | 1987-07-17 | 1999-04-06 | Calam And Associates, Inc. | Palatable liquid-admininstered oral medicaments for relief of discomfort and flavoring combinations therefor |
US5011688A (en) | 1989-02-02 | 1991-04-30 | Calam Henry D | Liquid composition for the relief of premenstrual and menstrual discomforts |
US6042812A (en) | 1996-11-26 | 2000-03-28 | The Procter & Gamble Company | Flavor systems for oral care products |
US7141555B2 (en) * | 2000-12-19 | 2006-11-28 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
BR0207930A (pt) * | 2001-03-05 | 2004-03-02 | Ortho Mcneil Pharm Inc | Composições farmacêuticas lìquidas com sabor mascarado |
RU2435569C2 (ru) * | 2006-03-16 | 2011-12-10 | Трис Фарма, Инк. | Композиции с модифицированным высвобождением, содержащие комплексы лекарственное вещество - ионообменная смола |
FI20080351A0 (fi) * | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi |
EP2117506A2 (en) | 2006-12-13 | 2009-11-18 | Stephen M. Tuel | Methods of making pharmaceutical components for customized drug products |
US9119809B2 (en) * | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
CN105705135A (zh) * | 2013-11-08 | 2016-06-22 | 伊莱利利公司 | 阿托莫西汀溶液 |
GR1008531B (el) | 2014-03-21 | 2015-07-13 | Λαμδα Φαρμακευτικα Εργαστηρια Εφαμροσμενης Ερευνας Και Αναπτυξης Α.Ε., | Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη |
-
2016
- 2016-12-14 US US15/379,142 patent/US9855228B1/en active Active
-
2017
- 2017-07-13 WO PCT/US2017/041937 patent/WO2018111345A1/en active Application Filing
- 2017-07-13 CN CN201780075467.4A patent/CN110035741B/zh active Active
- 2017-07-18 AR ARP170102007A patent/AR109093A1/es unknown
- 2017-07-18 TW TW106123887A patent/TWI646958B/zh active
- 2017-11-29 US US15/825,957 patent/US9993445B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2018111345A1 (en) | 2018-06-21 |
CN110035741B (zh) | 2022-06-07 |
US9993445B1 (en) | 2018-06-12 |
TWI646958B (zh) | 2019-01-11 |
US20180161289A1 (en) | 2018-06-14 |
CN110035741A (zh) | 2019-07-19 |
US9855228B1 (en) | 2018-01-02 |
TW201821070A (zh) | 2018-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR109093A1 (es) | Solución oral que comprende clorhidrato de atomoxetina y sus métodos | |
ES2605495T3 (es) | Solución de atomoxetina | |
BR112013031406A2 (pt) | forma de dosagem oral comestível em tira ou disco contendo resina de troca iônica para mascarar o sabor | |
AR108594A2 (es) | Formulaciones farmacéuticas que conservan el sabor con características farmacéuticas mejoradas | |
CO6300932A2 (es) | Composicion solida termoestable que comprende sustancias mejoradas de permeabilidad para ingredientes farmaceuticos activos de permeabilidad deficiente | |
CL2020000747A1 (es) | Formulaciones de niraparib. | |
BR112014013650A2 (pt) | "formulações de pulverização oral e seus usos" | |
ES2617252T3 (es) | Solución oral que comprende clorhidrato de atomoxetina | |
CL2019003533A1 (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
CO6491061A2 (es) | Formulacion de omeprazol farmaceutica estable para administracion oral | |
JP2019530706A5 (es) | ||
RU2015134148A (ru) | Галеновая форма для введения активного действующего вещества | |
ITTO20120776A1 (it) | Procedimento per mascherare l'amaro di un filtro uv | |
ECSP17064188A (es) | Formulación estable para administración parenteral de tapentadol | |
TR201819662T4 (tr) | Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi. | |
CO2018014217A2 (es) | Composiciones farmacéuticas que comprenden safinamida | |
EA201270745A1 (ru) | Улучшенный стабильный водный состав (e)-4-карбоксистирил-4-хлорбензилсульфона | |
AR042598A1 (es) | Composiciones de acetaminofeno | |
EA201791191A1 (ru) | Водные фармацевтические композиции для местного применения в ротовой полости, содержащие флурбипрофен и декспантенол | |
AR043412A1 (es) | Formulaciones farmaceuticas que comprenden un agente enmascarante del sabor amargo | |
MX369760B (es) | Composición farmacéutica de citrato de sildenafilo en forma de suspensión para uso oral. | |
ES2475942B1 (es) | Composición farmacéutica de citrato de sildenafilo en forma de solución acuosa | |
CL2021000882A1 (es) | Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia. | |
AR085801A1 (es) | Uso de una composicion pulverizable que contiene ambroxol, metodo | |
RU2018140968A (ru) | Витаминный препарат |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |